alt  

     Name:  Peeter Padrik

     Phone:  +372 731 9800

     E-mail:This email address is being protected from spambots. You need JavaScript enabled to view it.   

     Language competences:   estonian, english, russian

 

 

 

Employment and professional career

2017- ... Tartu University Hospital, Hematology and Oncology Clinic, Head of the Clinic

2016- ... Tartu University, Haematology and Oncology Clinic, Associate Professor (0,25)

2015- ... Tartu University Hospital, Cancer Centre, Director

2000- 2016 Tartu University Hospital, Hematology and Oncology Clinic, Director

2008-2016 Tartu University, Chair of Hematology and Oncology, Assistant in Oncology (0.20)

2009-2011 artu University, Chair of Hematology and OncologyResearcher (0.50)

1997-1999 Tartu University Hospital, Hospital of Oncology, Chief Physician

1996-1997 Tartu University Hospital, Hospital of Oncology, Deputy Chief Physician

1993-1996 Tartu University Hospital,Hospital of Oncology, Oncologist

1992-1993 Estonian Cancer Center, Oncologist

1991-1992 Estonian Institute of Experimental and Clinical Oncology, Junior Researcher

 

Education

1990-1991 Tartu Clinical Hospital, Internship in Surgery

1984-1990 University of Tartu, Faculty of Medicine

 

Administrative responsibilities

Estonian Society for Medical Oncology, Chairman of the Board

Oncology Commission of Estonian Ministry of Social Affairs, member

European Society for Medical Oncology, member

American Society of Clinical Oncology, member

 

 

Complementary education (last 5 years)

2014 European Society for Medical Oncology Congress

2014 American Society of Clinical Oncology Annual Meeting

2013-2014 SDA Bocconi School of Management (Milano) Program for Oncology Leaders in Europe

2013 American National Comprehensive Cancer Network Annual Conference

2013 Tartu Ülikooli arstiteaduskonna täienduskonverents Kliinik 

2012 Oncology Leaders Summit, Deutsche Gesellschaft für Senologi

2012 European Society for Medical Oncology Congress

2012 European Forum on Oncology

2012 Advances in Cancer Therapy

2011 European Multidisciplinary Cancer Congress

2011 St. Gallen – Breast Cancer Conference

2011 Tartu Ülikooli arstiteaduskonna täienduskonverents Kliinik

2011 5th International Breast Cancer Conference

2010 35th European Society for Medical Oncology Congress

2010 Worldwide Innovative Networking in Personalized Cancer Medicine Symposium

2010 European Multidisciplinary Cancer Congress

 

RESEARCH ACTIVITY

Academic degree:  PhD, 2007: “Renal Cell Carcinoma: Changes in Natural History and Treatment of Metastatic Disease”, Tartu University

Field of research:

Kidney cancer, breast cancer, melanoma

  

Publications (1.1-1.3)

1.1. 

Baburin, Aleksei; Aareleid, Tiiu; Padrik, Peeter; Valvere, Vahur; Innos, Kaire (2014). Time trends in population-based breast cancer survival in Estonia: Analysis by age and stage. Acta Oncologica, 53(2), 226 - 234.

Innos, K; Padrik, P; Valvere, V; Eelma, E; Kütner, R; Lehtsaar, J; Tekkel, M (2013). Identifying women at risk for delayed presentation of breast cancer: a cross-sectional study in Estonia . BMC Public Health, 13, 947
Vrdoljak, E.; Ciuleanu, T.; Kharkevich, G.; Mardiak, J.; Mego, M.; Padrik, P.; Petruželka, L.; Purkalne, G.; Shparyk, Y.; Skrbinc, B.; Szczylik, C.; Torday, L. (2012). Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. Expert Opinion on Pharmacotherapy, 13(2), 159 - 174.
Kasari, Marje; Padrik, Peeter; Vaasa, Angela; Saar, Kristi; Leppik, Krista; Soplepmann, Jaan; Uri, Asko (2012). Time-gated luminescence assay using nonmetal probes for determination of protein kinase activity-based disease markers. Analytical Biochemistry, 422(2), 79 - 88.
Steger, G.; Abrahámová, J.; Bacanu, F.; Brincat, S.; Brize, A.; Cesas, A.; Cufer, T.; Dank, M.; Duchnowska, R.; Eniu, A.; Jassem, J.; Kahán, Z.; Matos, E.; Padrik, P.; Pl?te, S.; Pokker, H.; Purkalne, G.; Timcheva, C.; Tzekova, V.; Vyzula, R.; Zielinski, C. (2010). Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener Klinische Wochenschrift, 122(11-12), 368 - 379.
Tamboom, K.; Kaasik, K.; Arsavskaja, J.; Tekkel, M., Lilleorg, A.; Padrik, P.; Metspalu, A.; Veidebaum, T. (2010). BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia. Hereditary Cancer in Clinical Practice, 8(4), 1 - 4.
Padrik, P.; Saar, H. (2009). Thymidine phosphorylase as a prognostic factor in renal cell carcinoma. International Urology and Nephrology, x - x.
Padrik, P.; Kirsimägi, Ü.; Everaus, H. (2007). Changes in the natural history of renal cancer: comparison of Estonian data from the periods 1986-1988 and 1996-1998. International Urology and Nephrology, 39(1), 35 - 41.
Padrik, P.; Leppik, K.; Arak, A. (2004). Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study. Urologic Oncology-Seminars and Original Investigations, 22(5), 387 - 392.
Bouzid, K.; Khalfallah, S.; Tujakowski, J.; Piko, B.; Purkalne, G.; Plate, S.; Padrik, P.; Serafy, M.; Pshevloutsky, E.; Boussard, B. (2003). A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Annals of Oncology, 14(7), 1106 - 1114.
Padrik, P. (2003). Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Medical Oncology, 20(4), 325 - 334.

1.3. 

Kallak, K.; Padrik, P. (2013). Tõenduspõhine rinnavähi kiiritusravi. Eesti Arst, 92(10), 575 - 580.

Padrik, P. (2011). Metastaatilise neeruvähi uued ravivõimalused . Eesti Arst, 90(1), 35 - 40.
Padrik, P., Eelma, E., Lehtsaar, J. (2007). Rinnavähi ravi arengusuunad . Eesti Arst, 86(11), 819 - 822.
Padrik, P.; Saar, H.; Leppik, K. (2006). Application of analysis of thymidine phosphorylase exprsssion in metastatic renal carcinoma tissue. Eesti Arst, 85(5), 297 - 300.
Padrik, P.; Saar, H.; Leppik, K. (2006). Tümidiini fosforülaasi ekspressiooni analüüsi rakendamine metastaatilise neeruvähiga patsientide kasvajakoes . Eesti Arst, 85(5), 297 - 300.
Padrik, P. (2002). Metastaatilise neeruvähi süsteemne ravi . Eesti Arst, 81(10), 631 - 637.